

## Chemotherapy Protocols

# GYNAECOLOGICAL CANCERS

Protocol	Hospital using the Protocol
Carboplatin Hypersensitivity Guidelines & Desensitisation Regimen	RSCH
<b>Ovarian and Uterine Cancers</b>	
Bevacizumab	RSCH
Caelyx & Carboplatin	RSCH
Carboplatin	RSCH, SASH
Cisplatin	RSCH
Cyclophosphamide oral (stored in urology section)	RSCH
Etoposide (oral)	RSCH
Gemcitabine and Carboplatin	RSCH, SASH
Gemcitabine & Docetaxel (stored in sarcoma section)	RSCH
Liposomal Doxorubicin (Caelyx)	RSCH
Olaparib	RSCH, SASH
Paclitaxel & Carboplatin	RSCH
Paclitaxel weekly & Carboplatin 3-weekly	RSCH
Paclitaxel & Cisplatin	RSCH
Weekly Paclitaxel	RSCH
Paclitaxel & Carboplatin & Epirubicin	RSCH
Topotecan	RSCH
<b>Cervical Cancer</b>	
Cisplatin & Etoposide	RSCH
Cisplatin and Radiotherapy	RSCH
Cisplatin & PVI 5FU (CF) – advanced use (also vulva and vagina)	RSCH
Cisplatin & PVI 5FU & RT	RSCH
Topotecan and Cisplatin	RSCH
<b>Cancer of Vulva</b>	
Cisplatin, 5FU and Radiotherapy	RSCH
Mitomycin C, 5FU and Radiotherapy	RSCH

RSCH = Royal Surrey County Hospital SASH = Surrey and Sussex Healthcare Trust

NB. The following reference sources were used routinely and are not individually referenced on each protocol:

Summary of Product Characteristics

Dose Adjustments for Cytotoxics in Renal and Hepatic Impairment, 2009 update, UCLH NHS Foundation Trust

Please note: the “Main Toxicities” section includes only predictable and/or important side effects. For more detailed information on side effects, please seek further literature.

Reason for Update: Olaparib and Cyclophos (oral) added	Prepared by: S Taylor
Version: 16	
Supersedes: Version 15	Date: June 2016